DK0941333T3 - Immunogent detoksificeret mutant E. Coli LT-A-toksin - Google Patents

Immunogent detoksificeret mutant E. Coli LT-A-toksin

Info

Publication number
DK0941333T3
DK0941333T3 DK97910583T DK97910583T DK0941333T3 DK 0941333 T3 DK0941333 T3 DK 0941333T3 DK 97910583 T DK97910583 T DK 97910583T DK 97910583 T DK97910583 T DK 97910583T DK 0941333 T3 DK0941333 T3 DK 0941333T3
Authority
DK
Denmark
Prior art keywords
coli
toxin
immunogenically
subunit
amino acid
Prior art date
Application number
DK97910583T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Marzia Monica Giuliani
Rino Rappuoli
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Application granted granted Critical
Publication of DK0941333T3 publication Critical patent/DK0941333T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
DK97910583T 1996-10-31 1997-10-30 Immunogent detoksificeret mutant E. Coli LT-A-toksin DK0941333T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622660.0A GB9622660D0 (en) 1996-10-31 1996-10-31 Immunogenic detoxified mutant toxin

Publications (1)

Publication Number Publication Date
DK0941333T3 true DK0941333T3 (da) 2006-01-02

Family

ID=10802210

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97910583T DK0941333T3 (da) 1996-10-31 1997-10-30 Immunogent detoksificeret mutant E. Coli LT-A-toksin

Country Status (10)

Country Link
US (2) US20030113338A1 (da)
EP (2) EP1571214A3 (da)
JP (2) JP3715326B2 (da)
AT (1) ATE303441T1 (da)
CA (1) CA2268758C (da)
DE (1) DE69734110T2 (da)
DK (1) DK0941333T3 (da)
ES (1) ES2247622T3 (da)
GB (1) GB9622660D0 (da)
WO (1) WO1998018928A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6219776B1 (en) 1998-03-10 2001-04-17 Billions Of Operations Per Second Merged array controller and processing element
SG121778A1 (en) 1998-10-09 2006-05-26 Univ Emory Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
BR9915533A (pt) * 1998-10-21 2001-11-06 Kitasato Inst Preparações de vacina contendo toxina atenuada
AU773953B2 (en) * 1998-12-22 2004-06-10 Boyce Thompson Institute For Plant Research Inc. Orally immunogenic bacterial enterotoxins expressed in transgenic plants
JP2005502591A (ja) * 2001-01-12 2005-01-27 カイロン コーポレイション 核酸粘膜免疫
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
EP2311481A3 (en) 2006-10-20 2013-10-16 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2010014358A (es) 2008-06-20 2011-07-04 Wyeth Llc Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas.
CN102307477B (zh) 2009-01-05 2015-07-29 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
AU2010301043B2 (en) 2009-06-22 2014-01-09 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MX2012000044A (es) 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
EP2632486A1 (en) 2010-10-27 2013-09-04 Harrisvaccines Inc Method of rapidly producing vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
BR112013016153A2 (pt) 2010-12-22 2017-07-11 Wyeth Llc composições imunogênicas estáveis de antígenos de staphylococcus aureus
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013066665A1 (en) 2011-10-19 2013-05-10 Harrisvaccines, Inc Method of rapidly producing improved vaccines for animals
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
SG10201602558UA (en) 2012-03-09 2016-05-30 Pfizer Neisseria meningitidis compositions and methods thereof
EP3363806B1 (en) 2012-12-20 2022-11-16 Pfizer Inc. Glycoconjugation process
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN106535930A (zh) 2014-03-11 2017-03-22 明尼苏达大学董事会 猪流行性腹泻病毒疫苗及其使用方法
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019217473A1 (en) * 2018-05-07 2019-11-14 The Administrators Of The Tulane Educational Fund Mutant e. coli enterotoxins as anti-inflammatory agents
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
US20230321212A1 (en) 2020-08-26 2023-10-12 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
JPWO2022196816A1 (da) * 2021-03-19 2022-09-22

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8333131D0 (en) * 1983-12-12 1984-01-18 Glaxo Group Ltd Microbiological process
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE69022106T2 (de) 1989-04-28 1996-02-15 Sclavo Spa Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis.
IT1248735B (it) 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
EA004794B1 (ru) 1998-05-08 2004-08-26 Юниверсити Оф Бристоль Вакцина
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン

Also Published As

Publication number Publication date
GB9622660D0 (en) 1997-01-08
US7291588B2 (en) 2007-11-06
ATE303441T1 (de) 2005-09-15
EP1571214A2 (en) 2005-09-07
JP3715326B2 (ja) 2005-11-09
WO1998018928A1 (en) 1998-05-07
CA2268758C (en) 2007-05-29
US20030113338A1 (en) 2003-06-19
CA2268758A1 (en) 1998-05-07
DE69734110D1 (de) 2005-10-06
DE69734110T2 (de) 2006-06-29
EP1571214A3 (en) 2006-03-29
EP0941333B1 (en) 2005-08-31
EP0941333A1 (en) 1999-09-15
US20030170262A1 (en) 2003-09-11
JP2005247868A (ja) 2005-09-15
ES2247622T3 (es) 2006-03-01
JP2001508286A (ja) 2001-06-26

Similar Documents

Publication Publication Date Title
DK0941333T3 (da) Immunogent detoksificeret mutant E. Coli LT-A-toksin
DK0835314T3 (da) Immunogen detoksificeret mutant af koleratoksiner
ITMI913513A1 (it) Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE187078T1 (de) Nichttoxisches schleimhautadjuvans
ATE476508T1 (de) Neisseriale antigene
CA2437899A1 (en) Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
DK1047784T3 (da) Neissera meningitidis-antigener
ATE229978T1 (de) Helicobacter proteine und impstoffe
CA2154063A1 (en) Treatment of h. pylori associated gastroduodenal disease
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
DE69510858D1 (de) Mukosale Verabreichung von Pneumokokken-Antigenen